Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06602271 | PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) | PHASE3 | RECRUITING | 320 | — | — | Dec 9, 2025 | Nov 1, 2026 | Jan 22, 2026 | 3 | United States |
Pain at rest
| Arm | Type | Description |
|---|---|---|
| PF614 25 mg | EXPERIMENTAL | Oral administration every 12 hours |
| PF614 37.5 mg | EXPERIMENTAL | Oral administration every 12 hours |
| PF614 50 mg | EXPERIMENTAL | Oral administration every 12 hours |
| Placebo | PLACEBO_COMPARATOR | Oral administration every 12 hours |
| Name | Type | Description |
|---|---|---|
| PF614 capsule | DRUG | Experimental oxycodone prodrug |
| Placebo | DRUG | Inactive medication |
Inclusion Criteria: 1. Participant must provide written informed consent prior to the initiation of any protocol specific procedures. 2. Male or female participant, between 18 and 75 years of age, inclusive, at the time of Screening. 3. Participant must be scheduled to undergo a full abdominoplasty...